Free Trial
LON:NCYT

Novacyt (NCYT) Share Price, News & Analysis

Novacyt logo
GBX 38.29 -1.81 (-4.51%)
As of 04/25/2025 11:08 AM Eastern

About Novacyt Stock (LON:NCYT)

Key Stats

Today's Range
38.02
39.83
50-Day Range
37.90
51
52-Week Range
36
137
Volume
38,637 shs
Average Volume
186,972 shs
Market Capitalization
£26.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental. The Company is divided into three business segments: Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments Research Use Only Range of services for the life sciences industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV"). For more information, please refer to the website: www.novacyt.com

Receive NCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novacyt and its competitors with MarketBeat's FREE daily newsletter.

NCYT Stock News Headlines

Trump’s tariffs just split the AI market in two
Trump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying on cheap foreign hardware—just saw their costs shoot through the roof. For the other group of AI companies, they were just handed a massive competitive advantage. Make no mistake, AI as a whole is still a game-changer for the global economy. But within the AI sector, Trump’s tariffs have created a huge divergence.
Update re. Lab 21 HSE Prosecution
See More Headlines

NCYT Stock Analysis - Frequently Asked Questions

Novacyt's stock was trading at GBX 49.30 at the start of the year. Since then, NCYT stock has decreased by 22.3% and is now trading at GBX 38.29.
View the best growth stocks for 2025 here
.

Shares of NCYT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novacyt investors own include BP (BP), Mesa Air Group (MESA), Global X Cloud Computing ETF (CLOU), genedrive (GDR), Invesco High Yield Equity Dividend Achievers ETF (PEY), Walmart (WMT) and boohoo group (BOO).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
Current Symbol
LON:NCYT
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-36,800,438.95
Net Margins
-203.06%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£18.12 million
Cash Flow
GBX 65.98 per share
Price / Cash Flow
0.58
Book Value
GBX 99.62 per share
Price / Book
0.38

Miscellaneous

Free Float
N/A
Market Cap
£26.46 million
Optionable
Not Optionable
Beta
-1.86
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (LON:NCYT) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners